Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
复制标题
DOI：
10.1038/s41591-019-0437-z
复制
发表时间：
2019-05-01
期刊：
影响因子：
82.9
通讯作者：
Spencer, Helen
中科院分区：
文献类型：
--
作者：
Dedrick, Rebekah M.;Guerrero-Bustamante, Carlos A.;Spencer, Helen
一名15岁的囊性纤维化伴弥散性脓肿分枝杆菌感染的患者在双侧肺移植后接受了三噬菌体鸡尾酒治疗。利用基因工程和正向遗传技术，开发了高效杀伤感染性脓肿分枝杆菌的噬菌体衍生物。静脉噬菌体治疗耐受性良好，并与客观临床改善相关，包括胸骨伤口愈合、肝功能改善和感染皮肤结节的实质性解决。
A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement, including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules.